{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T19:30:23Z","timestamp":1754163023193,"version":"3.41.2"},"reference-count":38,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"unspecified","delay-in-days":27,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Glob Health"],"accepted":{"date-parts":[[2025,5,3]]},"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:p>Critical voices on unfairly high mpox and other vaccine prices open the debate on the \u2018right price\u2019 to be paid to private vaccine suppliers. We apply compound real options analysis as a more appropriate valuation method to derive a correct firm\u2019s break-even price. Real option models are better able to capture the development costs, associated risks and the embedded operational flexibility in vaccine development in a superior way compared with more traditional net present value (NPV) methods. The real option price is lower than standard NPV-based methods, thereby providing a basis to improve the bargaining position of payers in negotiating better vaccine price outcomes. Deeper insights into the correct break-even price will create a more balanced playing field between firms and payers. This can also lead to more equitable access to vaccines in developing countries.<\/jats:p>","DOI":"10.1136\/bmjgh-2024-018390","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T03:15:19Z","timestamp":1748488519000},"page":"e018390","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["The role of the right valuation method in setting the firm\u2019s break-even price for mpox (and other) vaccines"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0578-5460","authenticated-orcid":false,"given":"Peter-Jan","family":"Engelen","sequence":"first","affiliation":[{"name":"Utrecht School of Economics, Utrecht University, Utrecht, Netherlands"},{"name":"Faculty of Business and Economics, University of Antwerp, Antwerpen, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danny","family":"Cassimon","sequence":"additional","affiliation":[{"name":"IOB, University of Antwerp, Antwerpen, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,5,28]]},"reference":[{"key":"2025073014412648000_10.5.e018390.1","unstructured":"Gavi signs agreement with bavarian nordic to rapidly secure 500,000 doses of mpox vaccines for africa. 2024. Available: https:\/\/www.gavi.org\/news\/media-room\/gavi-signs-agreement-bavarian-nordic-rapidly-secure-500000-doses-mpox-vaccines"},{"key":"2025073014412648000_10.5.e018390.2","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.q2174","article-title":"Mpox: Africa\u2019s response is obstructed by manufacturer\u2019s failure to share vaccine technology and unfair pricing, says campaign group","volume":"387","author":"Nakweya","year":"2024","journal-title":"BMJ"},{"key":"2025073014412648000_10.5.e018390.3","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.n1467","article-title":"Future of covid-19 vaccine pricing: lessons from influenza","volume":"373","author":"Ramachandran","year":"2021","journal-title":"BMJ"},{"key":"2025073014412648000_10.5.e018390.4","doi-asserted-by":"publisher","DOI":"10.1177\/01410768211053006"},{"key":"2025073014412648000_10.5.e018390.5","doi-asserted-by":"crossref","unstructured":"Kremer M , Levin J , Snyder CM . Advance market commitments: insights from theory and experience. In AEA Papers and Proceedings 2020.269\u201373.","DOI":"10.1257\/pandp.20201017"},{"key":"2025073014412648000_10.5.e018390.6","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2020.00646"},{"key":"2025073014412648000_10.5.e018390.7","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.jval.2020.12.008","article-title":"How Should the World Pay for a Coronavirus Disease (COVID-19) Vaccine?","volume":"24","author":"Towse","year":"2021","journal-title":"Value Health"},{"key":"2025073014412648000_10.5.e018390.8","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1093\/ajhp\/65.004","article-title":"Pharmaceutical reimbursement: an overview","volume":"65","author":"Johnson","year":"2008","journal-title":"Am J Health Syst Pharm"},{"key":"2025073014412648000_10.5.e018390.9","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/S0140-6736(11)60687-9","article-title":"Making new vaccines affordable: a comparison of financing processes used to develop and deploy new meningococcal and pneumococcal conjugate vaccines","volume":"378","author":"Hargreaves","year":"2011","journal-title":"The Lancet"},{"key":"2025073014412648000_10.5.e018390.10","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.copbio.2016.03.002","article-title":"Improving global vaccine accessibility","volume":"42","author":"Hill","year":"2016","journal-title":"Curr Opin Biotechnol"},{"key":"2025073014412648000_10.5.e018390.11","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.11.087700"},{"key":"2025073014412648000_10.5.e018390.12","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S2213-2600(15)00194-0","article-title":"Pricing of pneumococcal conjugate vaccine challenged","volume":"3","author":"Burki","year":"2015","journal-title":"Lancet Respir Med"},{"key":"2025073014412648000_10.5.e018390.13","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.respol.2005.12.005","article-title":"Application of real options analysis for pharmaceutical R&D project valuation\u2014Empirical results from a survey","volume":"35","author":"Hartmann","year":"2006","journal-title":"Res Policy"},{"key":"2025073014412648000_10.5.e018390.14","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.irfa.2015.05.026","article-title":"The use of real option theory in Scandinavia\u2019s largest companies","volume":"41","author":"Horn","year":"2015","journal-title":"International Review of Financial Analysis"},{"key":"2025073014412648000_10.5.e018390.15","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1080\/00137910701503910","article-title":"Are \u201cReal Options\u201d Actually Used in the Real World?","volume":"52","author":"Block","year":"2007","journal-title":"The Engineering Economist"},{"key":"2025073014412648000_10.5.e018390.16","doi-asserted-by":"publisher","DOI":"10.1002\/hec.1176"},{"key":"2025073014412648000_10.5.e018390.17","unstructured":"Luehrman TA . Investment opportunities as real options: getting started on the numbers. Harvard Business Review; 1998."},{"key":"2025073014412648000_10.5.e018390.18","unstructured":"Shockley R . An applied course in real options valuation. Thomson South-Western, USA, 2007."},{"key":"2025073014412648000_10.5.e018390.19","doi-asserted-by":"crossref","unstructured":"Dixit AK , Pindyck RS . Investment under uncertainty. Princeton university press, 1994.","DOI":"10.1515\/9781400830176"},{"key":"2025073014412648000_10.5.e018390.20","unstructured":"Trigeorgis L . Real options: managerial flexibility and strategy in resource allocation. USA: The MIT Press, 1996."},{"key":"2025073014412648000_10.5.e018390.21","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0048-7333(03)00089-1","article-title":"Valuing new drug applications using n-fold compound options","volume":"33","author":"Cassimon","year":"2004","journal-title":"Res Policy"},{"key":"2025073014412648000_10.5.e018390.22","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.respol.2011.05.020","article-title":"Incorporating technical risk in compound real option models to value a pharmaceutical R&D licensing opportunity","volume":"40","author":"Cassimon","year":"2011","journal-title":"Res Policy"},{"key":"2025073014412648000_10.5.e018390.23","unstructured":"Leslie K , Michaels M . The real power of real options. McKinsey Quarterly; 1997.97\u2013108."},{"key":"2025073014412648000_10.5.e018390.24","unstructured":"Damodaran A . Applied corporate finance. Wiley, 2015:656"},{"key":"2025073014412648000_10.5.e018390.25","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.healthpol.2022.12.006","article-title":"The long process by which HTA became a paradigm: A longitudinal conceptual structure analysis","volume":"127","author":"Belfiore","year":"2023","journal-title":"Health Policy"},{"key":"2025073014412648000_10.5.e018390.26","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-017-0509-1"},{"key":"2025073014412648000_10.5.e018390.27","doi-asserted-by":"publisher","DOI":"10.2469\/faj.v56.n3.2362"},{"key":"2025073014412648000_10.5.e018390.28","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1007\/s11606-020-06244-9","article-title":"Expert Forecasts of COVID-19 Vaccine Development Timelines","volume":"35","author":"Kane","year":"2020","journal-title":"J Gen Intern Med"},{"key":"2025073014412648000_10.5.e018390.29","doi-asserted-by":"crossref","unstructured":"Lo AW , Siah KW , Wong CH . Estimating Probabilities of Success of Vaccine and Other Anti-Infective Therapeutic Development Programs. Harvard Data Science Review 2020. doi:10.1162\/99608f92.e0c150e8","DOI":"10.1162\/99608f92.e0c150e8"},{"key":"2025073014412648000_10.5.e018390.30","doi-asserted-by":"crossref","first-page":"326","DOI":"10.7326\/M20-5350","article-title":"Probability of Success and Timelines for the Development of Vaccines for Emerging and Reemerged Viral Infectious Diseases","volume":"174","author":"MacPherson","year":"2021","journal-title":"Ann Intern Med"},{"key":"2025073014412648000_10.5.e018390.31","doi-asserted-by":"crossref","first-page":"e1386","DOI":"10.1016\/S2214-109X(18)30346-2","article-title":"Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study","volume":"6","author":"Gouglas","year":"2018","journal-title":"Lancet Glob Health"},{"key":"2025073014412648000_10.5.e018390.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2024.01.017"},{"key":"2025073014412648000_10.5.e018390.33","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/s41591-023-02229-3","article-title":"Real-world effectiveness of a single dose of mpox vaccine in males","volume":"29","author":"Wolff Sagy","year":"2023","journal-title":"Nat Med"},{"key":"2025073014412648000_10.5.e018390.34","doi-asserted-by":"crossref","DOI":"10.1093\/immadv\/ltad020","article-title":"Efficacy of smallpox vaccines against Mpox infections in humans","volume":"3","author":"Christodoulidou","year":"2023","journal-title":"Immunother Adv"},{"key":"2025073014412648000_10.5.e018390.35","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.technovation.2010.12.004","article-title":"Compound real option valuation with phase-specific volatility: A multi-phase mobile payments case study","volume":"31","author":"Cassimon","year":"2011","journal-title":"Technovation"},{"key":"2025073014412648000_10.5.e018390.36","doi-asserted-by":"crossref","unstructured":"Villa F , Tutone M , Altamura G , et al . Determinants of price negotiations for new drugs. The Experience of the Italian Medicines Agency, Health Policy 2019. doi:10.1016\/j.healthpol.2019.03.009","DOI":"10.1016\/j.healthpol.2019.03.009"},{"key":"2025073014412648000_10.5.e018390.37","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.jval.2022.11.015","article-title":"Medicare Drug Price Negotiation in the United States: Implications and Unanswered Questions","volume":"26","author":"Sullivan","year":"2023","journal-title":"Value Health"},{"key":"2025073014412648000_10.5.e018390.38","doi-asserted-by":"crossref","first-page":"101853","DOI":"10.1016\/j.ejpoleco.2020.101853","article-title":"Positioning and negotiations: The case of pharmaceutical pricing","volume":"62","author":"Grepperud","year":"2020","journal-title":"Eur J Polit Econ"}],"container-title":["BMJ Global Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgh-2024-018390","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T21:42:28Z","timestamp":1753911748000},"score":1,"resource":{"primary":{"URL":"https:\/\/gh.bmj.com\/lookup\/doi\/10.1136\/bmjgh-2024-018390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":38,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5,28]]},"published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1136\/bmjgh-2024-018390"],"URL":"https:\/\/doi.org\/10.1136\/bmjgh-2024-018390","relation":{},"ISSN":["2059-7908"],"issn-type":[{"type":"electronic","value":"2059-7908"}],"subject":[],"published":{"date-parts":[[2025,5]]}}}